Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
Por:
Rosas J, Liaño FP, Cantó ML, Barea JMC, Beser AR, Rabasa JTA, Adsuar FM, Auli BV, López IF, Sainz AMG, Ramis PE, Ruiz L, Rebollo MLN, Lorido RH, Gomez-escolar L and COVID19-HMB Group
Ahead of Print:
28 nov 2020
Resumen:
OBJECTIVE: To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge. METHODS: Medical records of patients admitted with COVID19 and IP with PaO(2)/FiO(2)<300, treated with BARI and/or TCZ, and compared with patients who did not, were retrospectively reviewed. RESULTS: Sixty patients were included; 43 (72%) are males, mean age 67 (SD: 14) years (<50 years: 17%; 51-70: 30%; >70: 53%), with 8.5 (SD: 1) days of symptoms. Sixteen (27%) patients required ICU (94% in <70 years). Fifteen (25%) patients died, 67% in >70 years; 11 (18%) patients died in the first 15 days of admission and 4 (7%) between days 16 to 30. Twenty-three (38%) patients received BARI, 12 (52%) monotherapy (Group 1), during 6 (SD: 2.6) days on average, none required ICU and 2 (17%) died. Thirty-one (52%) patients received TCZ, 20 (33%) as monotherapy (Group 2), 16 (52%) patients required ICU and 4 (20%) died. In the 11 (18%) patients who received BARI (2.8 [SD: 2.5] days average) and TCZ combined (Group 3), 3 (27%) required ICU and died. There were no severe side effects in BARI or TCZ patients. In the 17 (28%) patients who received neither BARI nor TCZ (Group 4), none required ICU and 6 (35%) died. Mean (SD) PaO(2)/FiO(2) at admission between groups was respectively: 167 (82.3), 221 (114.9), 236 (82.3), 276 (83.2). CONCLUSION: Treatment with BARI and TCZ did not cause serious side effects. They could be considered early in patients with NI secondary to COVID19 and impaired PaO2/PaFi.
Filiaciones:
:
Rheumatology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Pneumology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Pharmacy Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Anesthesia Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Pneumology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Internal Medicine Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
Ruiz L:
Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Intensive Care Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
:
Neurology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
Gomez-escolar L:
Gastroenterology Department, Marina Baixa Hospital, Villajoyosa, Alicante, Spain
Open Access
FULL TEXT
 |
Published Version |
This policy does not allow for Open Access for this version. |
| No Accesible |
|